首页> 外文OA文献 >Formulation, preparation and in vitro - in vivo evaluation of compression-coated tablets for the colonic-specific release of ketoprofen
【2h】

Formulation, preparation and in vitro - in vivo evaluation of compression-coated tablets for the colonic-specific release of ketoprofen

机译:在酮洛芬的结肠特异性释放的压缩涂层片剂的制剂,制备和体外 - 体内评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ABSTRACT The aim of this study was to formulate and prepare compression-coated tablets for colonic release (CR-tablets), and to evaluate the bioavailability of ketoprofen following the administration of a single dose from mini-tablets with immediate release (IR-tablets) compared to CR-tablets. CR-tablets were prepared based on time-controlled hydroxypropylmethylcellulose K100M inner compression-coating and pH-sensitive Eudragit® L 30D-55 outer film-coating. The clinical bioavailability study consisted of two periods, in which two formulations were administered to 6 volunteers, according to a randomized cross-over design. The apparent cumulative absorption amount of ketoprofen was estimated by plasma profile deconvolution. CR-tablets were able to delay ketoprofen’s release. Compared to IR-tablets used as reference, for the CR-tablets the maximum plasma concentration (Cmax) was lower (4920.33±1626.71 ng/mL vs. 9549.50±2156.12 ng/mL for IR-tablets) and the time needed to reach Cmax (tmax) was 5.33±1.63 h for CR-tablets vs. 1.33±0.88 h for IR-tablets. In vitro-in vivo comparison of the apparent cumulative absorption amount of ketoprofen showed similar values for the two formulations. Therefore, the obtained pharmacokinetic parameters and the in vitro-in vivo comparison demonstrated the reliability of the developed pharmaceutical system and the fact that it is able to avoid the release of ketoprofen in the first part of the digestive tract.
机译:摘要该研究的目的是制备和制备用于结肠释放(Cr-Tablets)的压缩涂层片剂,并在用立即释放(IR-Pablets),从迷你片剂中施用单剂量后评价酮丙烯的生物利用度与Cr-tablets相比。基于时间控制的羟丙基甲基纤维素K100M内压缩涂层和pH敏感的Eudragit®130d-55外膜涂层制备Cr-tablets。根据随机交叉设计,临床生物利用度研究由两个时期组成,其中给予6个志愿者6个志愿者。通过血浆谱折叠估计酮丙烯的表观累积吸收量。 Cr-pablets能够延迟酮洛芬的释放。与用作参考的IR-片剂相比,对于Cr-tablets,最大血浆浓度(CMAX)较低(4920.33±1626.71ng / ml与IR-tablets的9549.50±2156.12ng / ml),并且达到CMAX所需的时间(Tmax)对于Cr-tablets的5.33±1.63h,对于IR-Tablets,1.33±0.88小时。体内体内的体内比较酮洛芬的表观累积吸收量显示了两种制剂的相似值。因此,所获得的药代动力学参数和体内体内比较示出了发达的药物系统的可靠性以及它能够避免在消化道的第一部分中释放酮洛芬的事实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号